Schmitz Ann Kristin, Munoz-Bendix Christopher, Remke Marc, Brozou Triantafyllia, Borkhardt Arndt, Hänggi Daniel, Beez Thomas
Department of Neurosurgery, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Department of Neurosurgery, Medical Faculty, University of Bonn, Bonn, Germany.
Brain Spine. 2022 Jan 20;2:100865. doi: 10.1016/j.bas.2022.100865. eCollection 2022.
Postoperative residual tumor can occur for intentional or unintentional reasons. Decision-making regarding second-look surgery has to weigh molecular biology, probability of total resection and prognostic relevance against potential additional morbidity. In interdisciplinary tumor boards the neurosurgeon has to estimate risk and efficacy of second-look surgery in individual cases, based on precise data.
Aim of this study was to provide such data by analyzing morbidity and volumetric efficacy of second-look surgery at a designated pediatric neuro-oncology unit.
Children who received second-look surgery in 2007-2018 after incomplete resections were analyzed retrospectively. Measurements were performed on early postoperative magnetic resonance imaging, comparing axial diameter-based measurement as well as computer-assisted volumetric analysis.
59 patients (37% of the overall cohort; 21 female; mean age: 8 ± 5 years) received a subtotal (n = 35) or near total (n = 24) resection. After interdisciplinary case review, 12 of these patients received second-look surgery mainly for residual ependymoma. This led to further tumor volume reduction in all cases (new degrees of resection: subtotal = 2, near total = 6, gross total = 4). No new permanent morbidity or perioperative mortality was observed.
Second-look surgery did not increase mortality and permanent morbidity, had an 8% rate of transient morbidity and achieved tumor volume reduction above 95% in 75% of selected cases, with 4 additional gross total resections. Second-look surgery is safe and effective with regard to volumetric outcome parameters even in cases with good initial resections, although the role of second-look surgery regarding oncological outcome has to be further investigated in times of personalized molecular medicine.
术后残留肿瘤可能因有意或无意的原因而出现。关于二次手术的决策必须权衡分子生物学、全切除的可能性和预后相关性与潜在的额外发病率。在多学科肿瘤委员会中,神经外科医生必须根据精确数据评估个别病例中二次手术的风险和疗效。
本研究的目的是通过分析指定儿科神经肿瘤科室二次手术的发病率和体积疗效来提供此类数据。
对2007年至2018年接受不完全切除后进行二次手术的儿童进行回顾性分析。在术后早期磁共振成像上进行测量,比较基于轴向直径的测量以及计算机辅助体积分析。
59例患者(占整个队列的37%;21例女性;平均年龄:8±5岁)接受了次全切除(n = 35)或近全切除(n = 24)。经过多学科病例审查,其中12例患者主要因残留室管膜瘤接受了二次手术。这导致所有病例的肿瘤体积进一步缩小(新的切除程度:次全切除 = 2例,近全切除 = 6例,全切除 = 4例)。未观察到新的永久性发病率或围手术期死亡率。
二次手术未增加死亡率和永久性发病率,短暂发病率为8%,在75%的选定病例中肿瘤体积缩小超过95%,另有4例实现了全切除。即使在初始切除良好的病例中,二次手术在体积结果参数方面也是安全有效的,尽管在个性化分子医学时代,二次手术在肿瘤学结果方面的作用仍需进一步研究。